The Venture Codex

Participated · Seed · May 2026

Signadori Bio is developing a next-generation, off-the-shelf immunotherapy approach that engineers monocytes in vivo to regulate and enhance myeloid anti-tumour activity. The company’s lead programme is SiB-2101, which it is advancing toward lead candidate nomination. Its platform and scientific approach are based on research conducted at Gustave Roussy and were developed by founders Dr Jean-Luc Perfettini and Professor Nathalie Chaput. Signadori is preclinical-stage and is based in Paris. Financially, the company has raised a total of €11.1 million following the recent seed extension, with backing from Sofinnova Partners, Invivo Partners, and new participation from Taiho Ventures. The company intends to use the funds to further develop its proprietary platform and to expand its scientific and operational teams to move toward clinical translation.

Participated · Series C · Apr 2026

STORM Therapeutics is a clinical-stage biotech headquartered in Cambridge, UK, led by CEO Jerry McMahon. Its lead candidate, STC-15, is an oral small-molecule inhibitor of METTL3 and is described as the first RNA‑modifying enzyme inhibitor to enter human clinical trials. STC-15 is currently being assessed as a monotherapy in a Phase 2 study for selected sarcoma indications, and the company has reported dosing the first patient in that study. In April 2026 STORM raised $56M in a Series C to support advancement of STC-15 and to enhance the Phase 2 program. The company’s core focus is developing therapies that target RNA modifications to reprogram malignant cells.

Led · Series B · Mar 2026

Crossbow Therapeutics is developing a portfolio of T-Bolt™ T-cell engager (TCE) therapies built from T-cell receptor-mimetic antibodies that target peptide–HLA (pHLA) complexes on cancer cells. Its lead program, CBX-250, is a first-in-class TCE targeting a pHLA specific to myeloid cancer cells and is being evaluated in the ongoing CROSSCHECK-001 Phase 1 trial in relapsed and refractory myeloid malignancies. The company is advancing CBX-663, a TCE targeting a TERT-derived pHLA, toward IND submission and a planned Phase 1 start in Q3 2026 for multiple hematologic and solid tumors. Crossbow positions its T-Bolt™ platform as broadly adaptable to address intracellular cancer targets previously unreachable by antibodies. The company will present preclinical data for both programs at the AACR 2026 Annual Meeting and expects initial clinical data from CBX-250 around the end of 2026. The recent $77 million Series B is intended to fund completion of CBX-250’s Phase 1 and to accelerate initiation and development of additional T-Bolt™ programs.

Participated · Series B · Jan 2026

EpiBiologics is a San Mateo–based biotechnology company pioneering the degradation of disease-driving extracellular membrane and soluble proteins via its proprietary EpiTAC bispecific antibody platform. The company’s lead candidate, EPI-326, is designed to degrade all oncogenic forms of EGFR in a tumor-selective manner, aiming to overcome safety and resistance limitations of current EGFR therapies. Preclinical data show strong, durable efficacy with favorable safety and pharmacokinetic profiles, supporting both monotherapy and combination use across multiple cancer types. EpiBiologics plans to commence a first-in-human trial of EPI-326 in early 2026 for non-small cell lung cancer and head and neck squamous cell carcinoma. Proceeds from its recent financing will also expand a broader pipeline in oncology and immunology while bolstering internal capabilities. The company recently strengthened its leadership team by hiring Eric Humke, M.D., Ph.D., as Chief Medical Officer and Aaron Mishel as Chief Financial Officer, and added several industry leaders to its Board.

Participated · Series B · Jan 2025

Normunity is a biotechnology company creating novel anti-cancer therapies that address untapped biology at the interface of the immune system and tumors. Its lead program, NRM-823, is a first-in-class T cell engager that binds a novel, highly specific tumor target expressed on multiple solid tumors. The company plans to initiate a Phase 1 clinical trial of NRM-823 in 2H 2025 and to advance other modalities against the same tumor-specific target, including antibody-drug conjugates and radiotheranostics. Normunity is building a pipeline of therapeutic antibodies, bispecific antibodies, and payload-carrying biologics derived from its proprietary target discovery process conducted in collaboration with the lab of Professor Lieping Chen at Yale. The recent $75 million Series B financing will be used to advance NRM-823 into the clinic and to broaden the pipeline of programs that address tumor-specific immune suppression. Normunity is located in Boston, MA and New Haven, CT. Normunity is creating a new class of precision immuno-oncology agents called immune normalizers that aim to free the body’s normal immunity against cancer. Its initial pipeline programs target mechanisms that drive the exclusion of T cells from immune-sensitive tumors and seek to render 'cold' tumors immune-responsive. The company was launched from an academic–biotech partnership with the Lieping Chen lab at Yale School of Medicine and leverages proprietary discovery platforms from that lab. Normunity says its collaborative, iterative model jointly interrogates and validates emerging targets preclinically and clinically. Leadership includes founding CEO Rachel Humphrey and scientific founder Lieping Chen, and the team is described as experienced in discovery and clinical advancement of cancer drugs. The Series A financing announced will enable advancement of the emerging pipeline into the clinic and expansion of the lab-based discovery platforms.